All entries for: Syntis Bio

Syntis Bio raised an additional $5 million to continue developing late-stage preclinical oral therapies that leverage intestinal biology to treat metabolic and rare diseases through daily, nutrient-blocking formulations.

Syntis Bio received a $33 million to advance its oral therapy platform for obesity, diabetes, and rare metabolic diseases. The company’s nutrient-blocking pill leverages transient polymer coatings and gut-stable enzyme therapies to provide a non-surgical treatment option that mimics the benefits of bariatric surgery while expanding therapeutic possibilities for rare metabolic disorders.